Charles Duncan

The selling in Cassava Sciences, Inc. (NASDAQ: SAVA) stock is continuing unabated amid the controversy surrounding its Alzheimer's study data. The Cassava Analyst: Cantor Fitzgerald analyst Charles Duncan suspended the Neutral rating and $109 price target on Cassava shares. The Cassava...

A Cantor Fitzgerald analyst is incrementally bullish on shares of Anavex Life Sciences, Corp (NASDAQ: AVXL) after the release of Phase 2 data for the company's lead candidate. The Anavex Analyst: Charles Duncan, Ph.D. maintained an Overweight rating on Anavex Life Sciences and raised...

Novavax, Inc. (NASDAQ: NVAX) announced late Thursday the initiation of a late-stage study of its investigational coronavirus vaccine, NVX-CoV2373, in the U.K. The Novavax Analysts: H.C. Wainwright analyst Vernon Bernardino reiterated a Buy rating on Novavax with a $290 price target...

Novavax, Inc. (NASDAQ: NVAX) shares were moving solidly higher Thursday following the publication of detailed results of the Phase 1 study of its coronavirus vaccine candidate in the New England Journal of Medicine.  The Novavax Analyst: Cantor Fitzgerald analyst Charles Duncan has an...

Inovio Pharmaceuticals Inc (NASDAQ: INO) failed to inspire confidence among investors despite revealing in its second-quarter earnings report that it is on track for a September start for a Phase 2/3 clinical study of its developmental DNA coronavirus vaccine.  The Inovio Analyst: Cantor...

Novavax, Inc.'s (NASDAQ: NVAX) presentation at the International Society for Vaccines virtual congress Tuesday has increased Cantor Fitzgerald's confidence in its investigational coronavirus vaccine, codenamed NVX-CoV2373. The Novavax Analyst: Charles Duncan reiterated an Overweight rating...

Novavax, Inc. (NASDAQ: NVAX) is landing financing deals that could help to successfully develop a vaccine for SARS-CoV, the virus that causes COVID-19. Novavax's Defense Department Funding  The Gaithersburg, Maryland-based biotech said late Thursday that it has been granted funding of up...

Novavax, Inc. (NASDAQ: NVAX), which last month landed CEPI funding for its coronavirus vaccine program, announced Tuesday the  initiation of human studies of its vaccine candidate, NVX-CoV2373. The Novavax Analysts Cantor Fitzgerald analyst Charles Duncan maintained an...

Coronavirus vaccine play Inovio Pharmaceuticals Inc (NASDAQ: INO) announced the completion of enrollment in the Phase 1 trial of its COVID-19 DNA vaccine INO-4800 and positive Phase 1/2a data for its MERS coronavirus vaccine INO-4700 on Tuesday. The Inovio Analysts Cantor Fitzgerald analyst...

Among the six coronavirus vaccine candidates that have entered human trials, two belong to publicly listed U.S. companies: Moderna Inc (NASDAQ: MRNA) and Inovio Pharmaceuticals Inc (NASDAQ: INO). Both stocks have rallied in reaction to updates on R&D and funding. Moderna is up...

The COVID-19-induced sell-off has taken a toll on stocks across sectors. An analyst at Cantor Fitzgerald presented his take on how biotech investing could look after the coronavirus pandemic and highlighted his top franchise picks among neuro and platform technology-enabled smid-cap biotechs. The...

GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH) shares are retreating following the release of fourth-quarter results. GW Pharmaceuticals reported quarterly losses of 7 cents per share, which beat the consensus estimate by 68 cents . This is a 65% increase over losses of 20 cents per share from the same...

Aimmune Therapeutics Inc (NASDAQ: AIMT) announced late Friday that it received FDA approval for Palforzia, its oral immunotherapy to treat peanut allergy. The Aimmune Analysts Baird analyst Brian Skorney maintained an Outperform rating and $64 price target for Aimmune shares. RBC Capital...

GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH) reported better-than-expected third-quarter revenues, thanks to strong sales of its cannabinoid epilepsy drug Epidiolex. The Analyst Bank of America analyst Tazeen Ahmad reiterated a Buy rating and $218 price target. (See track record here) Cantor...

Cantor Fitzgerald has high hopes for patients with rare and orphan diseases.  “We believe that biotech has entered a golden age of innovation and productivity across many therapeutic areas,” the firm said in a Friday note. Cantor expanded its portfolio with seven new neuro-...